https://www.selleckchem.com/pr....oducts/Perifosine.ht
The 3-year overall survival rate was significantly poorer in the primary progressors group than in the partial responders' group (15% vs. 48%, p0.001). Four of 17 patients treated with HDC-ASCT were primary progressors; only one patient survived without relapse. Although double-expressor lymphoma status did not significantly impact overall survival among all patients (p=0.794), it was identified as an independent poor prognostic factor in HDC-ASCT-treated patients (p=0.002). We identified a subgroup of patients with primary refra
Like
Comment
Share
